Natalizumab discontinuation in a Dutch real-world cohort
E M E Coerver1, M H J Wessels1, Z Y G van Lierop1
1Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Objective:
To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort.
Methods:
Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC.
Results:
Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity.
Conclusions:
JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.
More Related Videos
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
11:32Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists
Published on: October 18, 2024
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinical Trials: Overview
Bioequivalence studies: Biowaivers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
